AnaptysBio Inc - Asset Resilience Ratio
AnaptysBio Inc (ANAB) has an Asset Resilience Ratio of 11.52% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how AnaptysBio Inc's Asset Resilience Ratio has changed over time. Check AnaptysBio Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down AnaptysBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of AnaptysBio Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.99 Million | 11.52% |
| Total Liquid Assets | $37.99 Million | 11.52% |
Asset Resilience Insights
- Moderate Liquidity: AnaptysBio Inc has 11.52% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
AnaptysBio Inc Industry Peers by Asset Resilience Ratio
Compare AnaptysBio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for AnaptysBio Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for AnaptysBio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.15% | $73.44 Million | $364.39 Million | -34.06pp |
| 2024-12-31 | 54.21% | $262.29 Million | $483.83 Million | -24.25pp |
| 2023-12-31 | 78.46% | $354.94 Million | $452.39 Million | +17.85pp |
| 2022-12-31 | 60.61% | $369.93 Million | $610.38 Million | +52.46pp |
| 2021-12-31 | 8.14% | $52.37 Million | $643.07 Million | -26.23pp |
| 2020-12-31 | 34.38% | $143.20 Million | $416.55 Million | -12.32pp |
| 2019-12-31 | 46.69% | $203.21 Million | $435.20 Million | -14.90pp |
| 2018-12-31 | 61.59% | $313.49 Million | $509.00 Million | +10.82pp |
| 2017-12-31 | 50.77% | $167.22 Million | $329.36 Million | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more